RxDoctor Payments Data

Lindsey Bollaert

Family · Moline, ILNPI 1437604154

Payments from drug & device makers

$632in general payments, 2019–2025

Across 22 payments — averaging $28.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cvrx, Inc.$147
  • ZOLL Respicardia, Inc.$119
  • Novartis$98
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$82
  • Astellas Pharma US Inc$82
  • Sanofi-aventis U.S. LLC$36
  • plus $68 from 4 others

What the payments were for

  • Food & beverage$55087%
  • Education$8213%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$632 in reported general payments places this provider in the 65th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$43,822
Medicare patients
339
Services billed
578

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban131$163,194
EntrestoSacubitril/Valsartan52$55,313
XareltoRivaroxaban15$14,678
Metoprolol Succinate284$4,174
Flecainide Acetate63$3,145
Ranolazine ErRanolazine24$2,054
Carvedilol141$1,495
Lisinopril134$1,335
Amlodipine Besylate157$1,203
Losartan Potassium107$1,069
Metoprolol Tartrate122$994
Nifedipine ErNifedipine25$890
ClopidogrelClopidogrel Bisulfate73$853
Atorvastatin Calcium73$773
Isosorbide Mononitrate ErIsosorbide Mononitrate41$638

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$18$163,194131 claims
NovartisEntresto$98$55,31352 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,941 family providers in Illinois.

Other family in Moline

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →